• The big oil price recovery and bounce in ASX oil stocks are bringing out the bears

    Broker holding red flag in front of bear

    The ASX energy sector is on a tear since the oil price bounced from its unprecedented meltdown, but the bears might be ready to pounce again.

    In case you forgot, the WTI crude benchmark crashed into negative territory for the first time in history on April 20 before rebounding to US$35 a barrel while the Brent nearly doubled since bottoming to US$38 a barrel.

    The turnaround sent the Oil Search Limited (ASX: OSH) share price jumping 27% and the Santos Ltd (ASX: STO) share price climbing 25% over the period.

    These stocks are more leveraged to the oil price and explains why the Woodside Petroleum Limited (ASX: WPL) share price is trailing with “only” a 9% gain. But that’s still miles ahead of than the 5% increase in the S&P/ASX 200 Index (Index:^AXJO).

    More production cuts to support market

    However, the party for our energy producers may not last. Experts are casting doubt on the sustainability of the oil price rally even as OPEC and Russia (OPEC+) moved forward their meeting by a week to this Thursday.

    There’s speculation that the oil producing bloc will extend the supply cuts that triggered the recovery and moved their next meeting forward to speed things along.

    But Australia and New Zealand Banking GrpLtd’s (ASX: ANZ) commodities strategist Daniel Hynes told the Australian Financial Review that this could be a bearish sign instead.

    Oil party pooper

    OPEC+’s eagerness to bring forward their meeting and keep production quotas in place signify that demand for crude isn’t recovering at the same pace as prices.

    Demand for oil plummeted due to the COVID-19 shutdown of the global economy. While the gradual reopening of some countries is lifting demand for fuel, the recovery is patchy, especially as air travel remains off the cards.

    The widespread racial riots in the US sparked by the death of George Floyd is also hurting demand for the commodity.

    US drivers in a jam

    The US summer driving holiday season looks over before it began with Hynes saying that demand was down 25% to 30% over the Memorial Day holiday on May 25, which usually kicks off the season.

    “The US driver consumes about 10% of the world’s oil. So, it’s an important sector,” he told the AFR. “Any data highlighting how it’s going will be focused on.”

    Foolish takeaway

    While oil market looks prone to a pullback, or even a correction, its unlikely that we will see oil turn negative again.

    As I wrote back then, that was probably the only occasion time in our lifetime that we will witness such an event.

    This means the worst for the market is likely behind us, although the volatility means investors will need to reasonably strong stomach if they wanted to invest in ASX oil-exposed stocks.

    5 “Bounce Back” Stocks To Tame The Bear Market (FREE REPORT)

    Master investor Scott Phillips has sifted through the wreckage and identified the 5 stocks he thinks could bounce back the hardest once the coronavirus is contained.

    Given how far some of them have fallen, the upside potential could be enormous.

    The report is called 5 Stocks For Building Wealth after 50, and you can grab a copy for FREE for a limited time only.

    But you will have to hurry — history has shown the market could bounce significantly higher before the virus is contained, meaning the cheap prices on offer today might not last for long.

    See the 5 stocks

    More reading

    Motley Fool contributor Brendon Lau owns shares of Australia & New Zealand Banking Group Limited. Connect with me on Twitter @brenlau.

    The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The big oil price recovery and bounce in ASX oil stocks are bringing out the bears appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3domogV

  • 2 ASX 200 shares to watch on Tuesday

    trading, market, ASX, shares, investing

    ASX 200 shares had a strong start to the week as the S&P/ASX 200 Index (ASX: XJO) jumped 1.10% higher on Monday.

    The Resources sector led the benchmark index higher yesterday thanks to strong commodity prices. However, there were more mixed performances across other industries as the market volatility continued.

    Find out which ASX 200 shares I’m watching during today’s trade.

    2 ASX 200 shares to watch on Tuesday

    The BHP Group Ltd (ASX: BHP) share price is one I’m keeping my eye on today. Shares in the Aussie miner jumped 3.09% on Monday thanks to strong iron ore prices, although it has opened today down by 1.68%.

    At the time of writing, BHP is worth a whopping $169.1 billion and is the largest ASX 200 share by market capitalisation right now.

    Investors could continue to back the Aussie miner in 2020, but I still think its a speculative buy right now with so much uncertainty around trade.

    However, there are some tailwinds in the market right now which could push the BHP share price higher. Momentum could be a big factor and I think BHP is one ASX 200 share worth watching today.

    Other than BHP, Wesfarmers Ltd (ASX: WES) could be moving. Wesfarmers is an interesting business in a unique position right now.

    The Aussie conglomerate is sitting on a pile of cash after selling part of its stake in Coles Group Ltd (ASX: COL) for $1.1 billion. However, it’s not all good news for the ASX 200 share right now.

    The group is currently restructuring its retail arm, Kmart Group. In fact, Wesfarmers recently announced the closure of 75 Target stores as sales continue to slump.

    Despite opening slightly down this morning, the Wesfarmers share price has still climbed nearly 8% higher this year and is worth keeping on a watchlist. A strong balance sheet is a big plus and provides flexibility to buy more portfolio companies if the right opportunity arises.

    Foolish takeaway

    There are always many ASX 200 shares worth watching. These are just a couple of the large-caps that I’m keeping an eye during another big day of trade.

    Here are 5 more ASX shares that are worth watching in 2020.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET and Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 ASX 200 shares to watch on Tuesday appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/36RsALU

  • 3 ASX shares to buy and hold for the next 2 decades

    man and woman thinking with picture of lightbulbs

    There aren’t too many ASX shares that I’d feel comfortable about buying and committing to owning for two decades.

    But there are a few that I think could be solid ultra-long-term picks. They have shown their worth in the coronavirus so far. 

    Washington H. Soul Pattinson and Co. Ltd (ASX: SOL)

    Soul Patts could be one of the best ASX shares to invest for the long-term in. Only an exchange-traded fund (ETF) may have a better claim.

    It has already been listed on the ASX for over a century, so it clearly has great longevity. But I don’t think it’s on the cusp of irrelevance at all. It’s an investment conglomerate so it can change its investment holdings as time goes on. Soul Patts is apparently about to start investing in regional data centres, a big growth area right now. Current large investments include telecommunications, building products and resources. 

    Of the current shares in the ASX 200, I think Soul Patts could be among the group that will operate for the longest time into the future.

    The management team of Soul Patts themselves invest for the long-term within the company. So it has long-term characteristics. It is steadily increasing its dividend, which is another attractive future.

    Xero Limited (ASX: XRO)

    There are only two things certain in life (as the saying goes). Death and taxes. You can’t do a business tax return without tracking your income, expenses, assets and liabilities, then making financial statements. So why wouldn’t you want to use the best tools available?

    Xero is an ASX share that provides cloud accounting software and it’s resonating with clients across the world.

    It’s no surprise that Xero has a strong market share in New Zealand and Australia as it’s a local business with a great service. But it’s also growing at an extraordinary rate in the UK and doing well in other areas of the world.

    Xero generates attractive monthly cashflow at a very high gross profit margin. At the moment Xero is investing heavily for growth and it’s paying off. In two decades (or just one) it could be one of two clear market leader providers in the world.

    Wesfarmers Ltd (ASX: WES)

    Wesfarmers isn’t normally an ASX share I’d suggest is one of the best dividend shares, or one of the best growth shares. But I think it’s a great blue chip.

    It isn’t stuck being a bank or a miner. It will happily adjust what operating businesses it owns over time. Remember that it acquired and years later divested Coles Group Limited (ASX: COL). Wesfarmers isn’t afraid to make big, bold moves. Even if they don’t work out – look what happened to Bunnings UK and Ireland.

    The point is that Wesfarmers can acquire businesses to position it for future success. For example, it recently acquired a lithium miner and it also acquired online retailer Catch Group.

    Of course, its current businesses are also fantastic. Bunnings may be the best retail businesses in the country.

    Foolish takeaway

    I think all of these ASX shares would make very good ultra-long-term investments at the current prices. Xero may be able to generate the most growth if it keeps adding subscribers, but I prefer Soul Patts for its diversification.

    These three shares aren’t the only shares I’d consider for the next two decades. I’d also want to think about these leading shares…

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    The post 3 ASX shares to buy and hold for the next 2 decades appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2U2BLUC

  • Eli Lilly CEO Talks Coronavirus Treatment Progress: ‘This Is An Important Bridge Therapy’

    Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'Drugmaker Eli Lilly And Co (NYSE: LLY) started a human study of a potential antibody treatment for COVID-19 patients, and CEO David Ricks said on Fox Business that it is the first of its kind.Lilly's Brand New Medicine Eli Lilly's medicine to treat COVID-19 patients is the first of its kind, as it consists of antibodies found in a recovered patient's cells. In contrast, other drugs and therapies are merely "repurposed" from other uses, Ricks said.Eli Lilly scientists collaborated with Canada-based AbCellera to engineer a treatment out of the "very best one or two" antibodies it can find out of millions of cells, the CEO said. The initial study will consist of less than 40 patients, and results are expected in a "couple of weeks," he said. Lilly's Production Timeline Eli Lilly has already started the process of ramping up production for its hopeful therapy despite it being in the early stages of testing, Ricks said.The company expects to produce 100,000 or more doses that will be available in the fall, the CEO said.During the pandemic's peak, there were around 60,000 people in a hospital in the U.S., so 100,000 could treat every person, he said.Important Treatment Before Vaccine Eli Lilly wants to study how its medicine can be used to treat people to avoid the need of going to a hospital in the first place as part of an ambulatory treatment study.The company also wants to explore later on in the summer months how its treatment can be used among those most at risk and vulnerable."This is an important bridge therapy until a vaccination could arrive and even perhaps vaccination this kind of therapy could find an important use," the CEO said.Lilly shares were trading down slightly at $152.86 at the time of publication Monday.Related Links:Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine53% Of Americans 'Very Likely' To Get Coronavirus Vaccine, Rasmussen ReportsEli Lilly CEO David Ricks. Benzinga file photo by Dustin Blitchok. See more from Benzinga * Making Sense Of Why Consumers Are Switching Their Grocery Store Habits * Intermediate Options Strategy With Ally Invest's Brian Overby * Impossible Foods Scores Big Win In Legal Battle With Nestle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/3eGhY5i

  • How to value the big four ASX banks

    maginfying glass over dollar sign

    Yesterday, I explored how some of the current issues facing the ASX banks could be impacting their ‘bankability’. But to understand how banks are valued in the first place, you need to recognise how they differ from other type of stocks. For example, unlike regular industrial stocks, banks make money from borrowing, lending and aiding the flow of money throughout the economy. This makes them highly vulnerable to the economic cycle, and as an investor you need to know when they’re out of the money.

    You need to tread carefully when using a price-to-earnings ratio (P/E) and dividend yield to gauge how attractive ASX bank shares might be. That’s because bad debts or one-off items can compromise the sustainability of bank dividends, as shareholders discovered in 2007 when they were slashed to help prop up badly needed bank capital.

    It’s also important to understand that banks require some peculiar evaluation criteria when it comes to assessing their intrinsic value and business performance. If you do want to use the P/E ratio to help value and compare one bank share against another, then it must be used alongside some bank-specific financial ratios.

    While some valuation principles are equally applicable to all companies, there are a number of complications specific to banks. These include determining leverage – due to being both borrower and lender – regulatory impact, capital expenditure and interest margins.

    Key ratios

    Net interest margin (NIM): A bank’s primary income source is the difference between the interest income from its loan book, and interest paid out to depositors. Typically expressed as a percentage of the average loans outstanding over the period under review, this is known as the ‘net interest margin’ (NIM). A high ratio indicates bank efficiency. While you won’t find it in official financial statements, most banks disclose this average somewhere near the front of their detailed annual reports.

    Cost to income ratio: Measures a bank’s operating expenses as a percentage of its total income. The lower the ratio, the better the bank is at controlling costs and most brokers prefer banks with a cost to income ratio of less than 50%.

    Bad debts ratio: Measures a bank’s provisioning for when a client can’t meet their repayments and a debt goes bad. The higher the number of bad loans, the higher you really want the net interest margin to be, otherwise it could wipe out a hefty chunk of profit.

    Return on assets: As a useful efficiency measure for banks, ROA indicates how profitable a bank is relative to its total assets. Calculated by dividing annual earnings by its total assets, ROA is displayed as a percentage – the higher the better – and should reveal how competent management is at using its assets, like mortgages to generate earnings.

    Tier 1 capital ratio: Is a litmus test of a bank’s capital strength. It’s arrived at by isolating the amount of ‘tier 1 capital’ – the highest quality capital – then identifying the proportion of ‘risk-weighted assets’. Capital ratios in the big four and Macquarie range between 10.8% and 12.2%.

    Price to book ratio: Is the value you would see if the business was liquidated and liabilities paid out. A ratio of 1 indicates shareholders can only expect a return of book value. A ratio above 1 indicates the extent to which shareholders are potentially exposed to market risk.

    Standout ASX bank shares to buy now

    Based on its forecasted pre-provision operating profit per share growth over the next 3 years, Goldman Sachs’ preferred major bank exposure is National Australia Bank Ltd (ASX: NAB). It expects NAB’s revenue momentum to remain superior to its peers, driven by its overweight exposure to SME lending. While NAB has taken the lowest provision for bad debts, at 0.38%, its credit impairment charge as a percentage of loans is also considerably lower than its peers.

    At a share price of $17.95, the bank is still trading 40% down on its 52-week high of $30.00. Goldman Sachs also reiterates a buy on Australia and New Zealand GrpLtd (ASX: ANZ) shares, which at $18.05 are still trading 38% down on their 52-week high of A$29.30.

    Based on its strong deposit franchise, Commonwealth Bank of Australia (ASX: CBA) is seen as more vulnerable to the medium-term impact of lower rates. The bank also has the highest exposure to more competitive mortgages relative to its peers. Based on a valuation that’s more expensive in relative and absolute terms, Goldman Sachs concludes that NAB and ANZ offer a more attractive entry point at current levels.

    Similarly, while Westpac Banking Corp (ASX: WBC) has demonstrated better expense control, stronger margins, and better than expected housing growth, the stock is not regarded as a buy. This is due to risk of higher investment spend, plus the risk of elevated fines and asset quality deterioration. At $17.36, Westpac shares are trading at a 42% discount to its 52-week high of $30.05.

    Market uncertainty over banks’ fortunes is reflected in buy, hold and sell consensus broker recommendations on ANZ, NAB and Westpac. However, brokers unanimously agree that Commonwealth Bank is not a buy, with 12 out of 15 seeing it as a strong sell.

    Despite the recent rally, bank share prices still suffer from a negative sentiment overhang that pre-dates COVID-19. Yet if the GFC is any proxy, the post-crisis period bodes well for the sector.

    For 5 more shares set for post-COVID-19 growth, don’t miss the free report below.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor Mark Story has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post How to value the big four ASX banks appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Mo7FGQ

  • Canopy Growth: Things Are Worse Than Thought, Says Jefferies

    Canopy Growth: Things Are Worse Than Thought, Says JefferiesWhat is the worst thing an investor could hear from a market share leader? According to Jefferies’ analyst Owen Bennett, it is probably the need to "understand what consumers want.”And that’s just what Canopy Growth (CGC) has said. According to the analyst, the Canadian cannabis producer’s disappointing FQ4 results indicate “things are worse than thought.”Canopy's Q4 net revenue came in at C$107.9 million, well below the C$128.9 million estimate and down by 13% from the previous quarter. The enormous overall net loss of C$1.3 billion, amounted to C$3.72 per share, far worse that the Street’s expectation of C$0.59 per share. Cue investors running to the exit door and a drop of 20% in the following trading session.Bennett recently upgraded Canopy’s rating from Sell to Hold, based on the reasoning “top line pressures were better understood,” and under the impression cost saving actions were moving the company in the right direction.Pointing out the slim bull case for Canopy rested on “increased focus on cost structure and profit delivery,” the analyst believes the turnaround appears more sluggish than anticipated as evidenced by operating expenses. Instead of improving, these increased by 17% compared to the previous quarter.Additionally, looking ahead, Canopy reduced expectations, describing FY21 as a “transition year,” and taking off the table previous forecasts for when it would achieve positive adjusted EBITDA.Along with the letdown of the report, the tone coming from Canopy’s direction has not impressed Bennett, who said, “While it said it is addressing certain headwinds with a shift into value and more high THC offerings, what really concerned us was commentary around needing to "understand what consumers want", and "servicing different segments". This is just basics and an issue we flagged over 12 months ago when initiating (Canopy having a catch all brand with no segmentation) and is something that in our view should be addressed prior to legalisation, not over a year into it, and especially from a market share leader.”To this end, Bennett reiterated a Hold and has a C$22.00 (US$16) price target on Canopy shares. (To watch Bennett’s track record, click here)Most of Wall Street echoes a neutral point of view, with TipRanks analytics exhibiting Canopy Growth as a Hold. Based on 15 analysts tracked by in the last 3 months, 2 say Buy, 10 suggest Hold, while 3 recommends Sell. Meanwhile the 12-month average price target stands at C$22.44, which aligns with where the stock is currently trading. (See Canopy Growth stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/36Ptd8M

  • Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

    Attention Biotech Investors: Mark Your Calendar For June PDUFA DatesDespite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular entities were approved during the month and several other drugs also received the nod.Meanwhile, Blueprint Medicines Corp (NASDAQ: BPMC) faced disappointment at the FDA altar, as its NDA for avapritinib for treating fourth-line gastrointestinal stromal tumor was clamped with a complete response letter.Here are the key PDUFA dates scheduled for the unfolding month.Merck's Antibiotic Combo Up Before FDA For Label Expansion * Company: Merck & Co., Inc. (NYSE: MRK) * Type of Application: sNDA * Candidate: Recarbrio * Indication: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia * Date: June 4Recarbrio is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Viela Eyes Commercial Status With its Autoimmune Disorder Drug Approval * Company: Viela Bio Inc (NASDAQ: VIE) * Type of Application: BLA * Candidate: inebilizumab * Indication: neuromyelitis optica spectrum disorder, or NMOSD * Date: June 11The FDA accepted the BLA for the investigational anti-CD19 monoclonal antibody on April 27, 2019. NMOSD is a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.The company said in its first-quarter earnings release it has begun preparations for potential regulatory approval, hiring and training market access and sales teams and deploying MSLs. The company expects to commercialize the drug shortly after.Can Merck's Wonder Cancer Drug Snag Another Approval * Company: Merck * Type of Application: sBLA * Candidate: Keytruda * Indication: solid tumors * Date: June 16 * Merck announced April 7 FDA acceptance of the application with priority review. Keytruda as a monotherapy is being evaluated for treating adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment optionsUltragenyx Seeks Label Expansion For Partnered Drug To Treat Low Serum Phosphate Levels * Company: Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Kyowa Kirin * Type of Application: sBLA * Candidate: burosumab * Indication: hypophosphatemia * Date: June 18The FDA accepted the application for priority review Feb. 27. Burosumab is a fully human monoclonal IgG1 antibody, which works against the phosphaturic hormone FGF23. This hormone reduces serum levels of phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney.It has already been approved for the treatment of X-linked hypophosphatemia in adult and pediatric patients 6 months of age and older. The companies are now seeking label expansion to include the indication FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.Epizyme Looks To Strike It Rich With Another Tazemetostat Approval * Company: Epizyme Inc (NASDAQ: EPZM) * Type of Application: sNDA * Candidate: tazemetostat * Indication: follicular lymphoma * Date: June 18Tazemetostat was initially approved for epithelioid sarcoma in January, and has been sold under the brand name Tazverik. The regulatory application, which was accepted for priority review, seeks approval for the drug for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy.Can Second Time Be Charm For Nabriva? * Company: Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) * Type of Application: NDA * Candidate: Contepo * Indication: complicated urinary tract infection or cUTI * Date: June 19Nabriva's original NDA was rejected by the FDA in April 2019, with the regulatory agency handing down a complete response letter on the pretext of issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers.The company resubmitted the application in late December, and the FDA acknowledged the resubmission in mid-January.Evoke Knocks The FDA Altar After A Prior Rejection * Company: Evoke Pharma Inc (NASDAQ: EVOK) * Type of Application: NDA * Candidate: Gimoti * Indication: diabetic gastroparesis * Date: June 19Evoke faced a rejection at the FDA altar once, and resubmitted the application, which was accepted for review in January. GimotI is a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley Karyopharm Blood Cancer Drug On Track For Second Approval? * Company: Karyopharm Therapeutics Inc (NASDAQ: KPTI) * Type of Application: sNDA * Candidate: Selinexor * Indication: relapsed or refractory diffuse large B-cell lymphoma * Date: June 23Karyopharm announced on Feb. 19 FDA acceptance of the regulatory application, which sought accelerated approval for oral Selinexor tablets for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least two prior therapies.Selinexor was approved in July 2019 as a combo treatment option along with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma, who have received at least four prior therapies.Zogenix's Hopes For No Jitters On Seizure Drug Review * Company: Zogenix, Inc. (NASDAQ: ZGNX) * Type of Application: NDA * Candidate: Fintepla * Indication: seizures associated with Dravet syndrome * Date: June 25Zogenix's regulatory filing for Fintelpa was accepted for priority review in November 2019, with a PDUFA date of March 25. The FDA extended the review period by three months to give itself time to look at the additional data provided by the company.Heron Expects Gain From Pain Drug Review * Company: Heron Therapeutics Inc (NASDAQ: HRTX) * Type of Application: NDA * Candidate: HTX-011 * Indication: post-operative pain * Date: June 26Heron's HTX-011 is a combo drug consisting of bupivacaine and a low dose of non-steroidal anti-inflammatory drug meloxicam, and is a non-opioid pain drug. The NDA was originally submitted in October 2018, and in response to the application, the FDA issued a complete response letter in April 2019, citing the need for additional CMC and non-clinical information.Heron resubmitted the NDA in October 2019, and in February the company said the FDA extended the review period by three months, rendering the PDUFA data on June 26.If approved HTX-011 will compete with Pacira Biosciences Inc's (NASDAQ: PCRX) Exparel, Guggenheim Securities analyst Dana Flanders said in a recent note. Citing the firm's post-operative pain survey, Flanders said HTX-011 is likely to see significant growth at the expense of Exparel. The analyst said price point may be key in driving significant uptake.Can Chiasma Cross The FDA Hurdle This Time Around? * Company: Chiasma Inc (NASDAQ: CHMA) * Type of Application: NDA * Candidate: Mycapssa * Indication: acromegaly * Date: June 26The FDA accepted Chiasma's originally submitted NDA in August 2015.Mycapssa, or octreotide capsules, is an oral drug being evaluated for the maintenance therapy of adult patients with acromegaly. A complete response letter was issued by the FDA in April 2016, seeking an additional clinical trial to establish the efficacy. Following a resubmission in Dec. 2019, the FDA accepted the application in January, giving it a PDUFA date of June. 26.Acromegaly is a hormonal disorder that is caused by the production of too much hormone by the pituitary gland during adulthood, causing bone size to increase.Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine DevelopmentIntercept's Wait For NASH Drug May Not End * Company: Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Type of Application: NDA * Candidate: Obeticholic acid * Indication: fibrosis due to non-alcoholic steatohepatitis * Date: June 26NASH has become a tough nut to crack for biotech companies, with no approved drug yet despite a plethora of ongoing research. Intercept filed the NDA in November 2019 following positive Phase 3 results from the GENERATE study. The PDUFA date, which was originally fixed as March 26, was extended by three months.However, dimming the prospects, the company informed earlier this month an Adcom meeting scheduled tentatively for June 9 was postponed by the FDA. The company, therefore, indicated the review period is likely to be extended.See more from Benzinga * The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2XUBsg1

  • 3 cheap ASX manufacturing shares for the supply chain boom

    Manufacturing symbols overlaid on a manufacturing worker's profile

    In the wake of COVID-19, supply chains are already moving to become more local. For instance, there were acute shortages in healthcare, car parts and construction. In South Korea, Hyundai closed its plants due to a lack of car parts. Moreover, we all felt the impacts of a lack of hand sanitiser and face masks in the early days. 

    When we talk about Australian manufacturers, thoughts go immediately to PPE manufacturer Ansell Limited (ASX: ANN) or shipbuilder Austal Limited (ASX: ASB). Yet there are several smaller companies selling at share prices I believe are below their intrinsic value.

    Local supply chain manufacturing

    Reliance Worldwide Corporation Ltd (ASX: RWC) manufactures and sells plumbing accessories – a core product in the residential and commercial supply chains. Over the past 4 years since its initial public offering (IPO), the company has grown its sales by an average of 46.5%. At the same time, it is continually improving its net profits.

    Reliance has been acquiring companies to provide a comprehensive product offering. In addition, it operates in Australia, the UK and the US, providing exposure to the US housing market. The Reliance share price is selling at a price-to-earnings ratio of 20.51. This is well below the company’s 10 year P/E average and I believe Reliance is currently selling at a discount to its intrinsic value.

    Orora Ltd (ASX: ORA) manufactures packaging products. This includes bottles, boxes, cartons and aluminium cans. It operates in Australia and the US. Over the 6 years since its IPO, Orora has an average return on capital employed (ROCE) of 11%. This is a measure of how well the company can transform available capital into earnings. As companies move to localise supply chains, Orora is likely to see increased sales. 

    This share has a one-off payment this year after the sale of one of its business. When combined with the dividend payment, this share pays a 18.8% yield (based on last Friday’s share price). However, it must be purchased before the ex-dividend date of 19 June. 

    High tech manufacturing

    Of the 3 companies, Electro Optic Systems Hldg Ltd (ASX: EOS) is the smallest. It manufactures components for the defence and space sectors. Sales for this company have doubled for the past 2 years. It has recently completed the acquisition of Audacy Corporation, a US satellite communications company, which will provide the manufacturer with greater product diversity. Electro Optic provides high technology solutions, including the space situational awareness network in conjunction with the United States.

    The SpaceX launch over the weekend, combined with the recent Space Force announcement in the US and increases in defence spending, will likely see an increase in sales for this ASX mid cap. These are considered security critical areas. In my opinion, it would be a mistake to leave these areas in any concentrated and offshore manner, given the lessons from COVID-19. 

    Our free report has 5 cheap shares for growing wealth for life.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Daryl Mather owns shares of Austal Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Austal Limited and Reliance Worldwide Limited. The Motley Fool Australia owns shares of and has recommended Electro Optic Systems Holdings Limited. The Motley Fool Australia has recommended Ansell Ltd. and Reliance Worldwide Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 cheap ASX manufacturing shares for the supply chain boom appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2TYjyrk

  • The Energy Transition Is an Oil Refinery Making Renewable Diesel

    The Energy Transition Is an Oil Refinery Making Renewable Diesel(Bloomberg) — In a sign of changing times, a U.S. oil refining company is converting one of its plants into a producer of clean fuel.HollyFrontier Corp.’s Cheyenne refinery will stop using crude oil and be repurposed to pump out renewable diesel, which is typically made from soybean oil, recycled cooking oil and animal fats. That’s after processing margins plummeted on the collapse in fuel demand due to Covid-19-related lockdowns. Besides, the old facility’s maintenance costs were “uncompetitive,” and the government is promoting cleaner fuel production.It’s the latest example of how the traditional fossil fuel industry is changing amid rising calls for the protection of the environment and increased demand for green sources of energy. Cheaper renewable energy projects have already led to decreasing coal output across the U.S., and now — in the wake of oil’s historic crash — some fuel producers are grappling with diminished returns from turning crude into fuel.“Demand for renewable diesel, as well as other lower carbon fuels, is growing and taking market share based on both consumer preferences and support from substantial federal and state government incentive programs,” Mike Jennings, chief executive officer of HollyFrontier, said in a statement Monday.The company expects to spend $125 million to $175 million to re-purpose Cheyenne to produce about 90 million gallons per year of renewable diesel by the first quarter of 2022. The plant will stop consuming crude oil at the end of July this year, and 200 workers will be laid off, according to HollyFrontier.The conversion plan comes as dozens of small refineries nationwide brace for a big spike in costs to comply with the Renewable Fuel Standard, which mandates they blend biofuel into gasoline or buy tradable credits to comply. For years, many small refineries have won exemptions from the mandate, but under a federal appeals court ruling in January, only refineries that have continually been granted waivers can count on getting them in the future.HollyFrontier is effectively shedding the Cheyenne refinery’s biofuel-blending obligation under the RFS and transforming it into a plant that stands to benefit from the program.Using the converted plant, HollyFrontier will be able to produce not just renewable diesel encouraged by the RFS but also compliance credits that can be sold separately. However the transition comes with other costs, as fewer workers will be necessary to run the converted plant. The RFS is effectively forcing the closure of a plant that generated tax revenue and jobs for Wyoming and mandating its replacement be a smaller plant that employs far fewer people to sell fuel to California, said a refining industry official who asked not to be named discussing industry strategy.Senator John Barrasso, a Republican from Wyoming, called the job cuts at the Cheyenne refinery “devastating.” Although the Covid-19 pandemic has hurt oil refineries, Barrasso also pinned blame on the Environmental Protection Agency’s handling of the Renewable Fuel Standard.“EPA has failed to protect small refineries from unreasonable compliance costs under the Renewable Fuel Standard,” Barrasso said in an emailed statement. “Congress mandated the agency protect refineries under the Clean Air Act” and “relief from the RFS is critical to small refineries.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/36QpGap

  • Where to invest $5,000 into ASX 200 shares immediately

    asx growth shares to buy,

    This afternoon the Reserve Bank will make a decision on the cash rate. While there is speculation that rates could go to zero today, I’m not overly convinced this will be the case.

    However, what I am convinced about, is that rates will remain at ultra low levels for a long time to come.

    In light of this, if I had $5,000 in a savings account and no immediate use for it, I would invest it into the share market.

    Three top ASX 200 shares I would buy right now with these funds are named below:

    Appen Ltd (ASX: APX)

    Appen is a leading developer of high-quality, human annotated datasets for machine learning and artificial intelligence (AI). It has a team of over one million crowd-sourced experts preparing the data for the models of some of the world’s biggest tech companies. This is a vital part of the process and demand for its services is growing very strongly. And given the importance of AI and machine learning for big business, I expect this to be the case for a long time to come. In light of this, I believe Appen is well-placed to deliver strong earnings growth over the next decade.

    Aristocrat Leisure Limited (ASX: ALL)

    The Aristocrat Leisure share price has fallen heavily this year because of the pandemic. While its performance has inevitably been impacted by the crisis, I believe the selloff has been overdone. Especially given how I expect the gaming technology company to bounce back strongly when the crisis passes. This is due to its industry-leading poker machines and its growing digital business. The latter is experiencing very favourable tailwinds right now and is generating material recurring revenues.

    Bravura Solutions Ltd (ASX: BVS)

    Bravura Solutions is a growing financial technology company which offers a range of solutions to the wealth management and funds administration industries. While the company has a number of products in its portfolio, I’m most positive on the Sonata wealth management platform. This next generation wealth management platform has been a key driver of Bravura Solutions’ growth over the last few years. The good news is that I expect more of the same in the future thanks to it sizeable market opportunity.

    And if you have some funds leftover, these five recommendations below look like potential market beaters…

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Bravura Solutions Ltd. The Motley Fool Australia owns shares of Appen Ltd. The Motley Fool Australia has recommended Bravura Solutions Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Where to invest $5,000 into ASX 200 shares immediately appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2XUGRDy